• Search
  • Login
  • Register
Menu
  • Last issue
  • Home
  • News
  • CongressUpdate
  • Guidelines
  • Specials
  • Links
  • Reimbursement News
All
  • All
  • BJH articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here

Category

All
  • Alle
  • General
  • Healthy Living
  • Pharma News
  • Health of Tomorrow
  • Viewpoints
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical trials
  • Clinical practice
  • Corona
  • Medical Research
  • Health Innovation
  • Art on View
  • Podcasts
  • Therapy
  • Editor's pick
  • Covid-19
  • Society Announcement
  • Reimbursement News
  • Congress News

Specialty

All
  • Alle
  • YESCARTA
  • BEKEMV
  • NPLATE
Clinical trials

Enasitenib outperforms conventional care in pretreated older IDH2-mutant R/R AML patients

subscribe Latest issue All issues Newsletters
Index latest issue
  • INTRODUCTION
  • Advancements in thrombophilia testing: The role of multi-gene panels in venous thromboembolism
  • The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome
  • Desensitisation as treatment option in patients with drug hypersensitivity
  • HMB-001: Novel treatment for Glanzmann thrombasthenia
  • Anti-IL6 receptor antibody for the treatment of immune checkpointrelated hemophagocytic lymphohistiocytosis
  • Highlights from EBMT 2025
  • Journal scan
  • New haematology reimbursements in Belgium
Pharma News

FDA approves pirtobrutinib for the treatment of advanced relapsed/refractory mantle cell lymph...

Clinical trials

Lisocabtagene maraleucel meets its primary endpoint of complete response rate in R/R CLL and S...

General

Highlights from the annual BSTH meeting 2022

Pharma News

Zanubrutinib receives FDA approval for patients with CLL or SLL

Clinical practice

A new and efficient treatment regimen for patients undergoing allogeneic HSCT

Clinical practice

Safety data of lisocabtagene maraleucel supports its use in an outpatient setting

Previous 12 13 14 15 16 17 18 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJH
  • Advertisements & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJH is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJH 2025